| pubmed-article:11412343 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11412343 | lifeskim:mentions | umls-concept:C0024554 | lld:lifeskim |
| pubmed-article:11412343 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:11412343 | lifeskim:mentions | umls-concept:C0597719 | lld:lifeskim |
| pubmed-article:11412343 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11412343 | lifeskim:mentions | umls-concept:C0671870 | lld:lifeskim |
| pubmed-article:11412343 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:11412343 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
| pubmed-article:11412343 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:11412343 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11412343 | pubmed:dateCreated | 2001-6-19 | lld:pubmed |
| pubmed-article:11412343 | pubmed:abstractText | Orexin-A is synthesized in the posterolateral hypothalamus and immunoreactive fibres project to many central nervous system structures, including the paraventricular nucleus, which is rich in corticotropin releasing factor (CRF) neurones and neuropeptide Y (NPY) innervation. We investigated the central effects of orexin-A on the hypothalamic-pituitary-adrenal (HPA) axis by measuring plasma concentrations of corticosterone and adrenocorticotropic hormone (ACTH) in vivo. We explored the potential neuropeptide pathways involved by investigating the effects of orexin-A on CRF, NPY, arginine vasopressin (AVP) and noradrenaline release from hypothalamic explants in vitro. Intracerebroventricular (i.c.v.) injection of orexin-A (3 nmol) in male rats stimulated increases in plasma concentrations of corticosterone between 10 and 40 min after injection, and of plasma ACTH at 20 and 90 min after injection. Orexin-A significantly stimulated CRF and NPY release from hypothalamic explants in vitro. Orexin-A did not stimulate CRF release in the presence of the selective NPY Y1 receptor antagonist, BIBP3226. BIBP3226 alone did not alter CRF release from hypothalamic explants. Orexin-A had no effect in vitro on the release of other neuropeptides, AVP and noradrenaline, involved in the central regulation of the HPA axis. These results suggest that orexin-A is involved in activation of the HPA axis, and that these effects could be mediated via the release of NPY. | lld:pubmed |
| pubmed-article:11412343 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11412343 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11412343 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11412343 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11412343 | pubmed:issn | 0953-8194 | lld:pubmed |
| pubmed-article:11412343 | pubmed:author | pubmed-author:BloomS RSR | lld:pubmed |
| pubmed-article:11412343 | pubmed:author | pubmed-author:MorganD GDG | lld:pubmed |
| pubmed-article:11412343 | pubmed:author | pubmed-author:GhateiM AMA | lld:pubmed |
| pubmed-article:11412343 | pubmed:author | pubmed-author:AbbottC RCR | lld:pubmed |
| pubmed-article:11412343 | pubmed:author | pubmed-author:RussellS HSH | lld:pubmed |
| pubmed-article:11412343 | pubmed:author | pubmed-author:SmallC JCJ | lld:pubmed |
| pubmed-article:11412343 | pubmed:author | pubmed-author:DakinC LCL | lld:pubmed |
| pubmed-article:11412343 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11412343 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:11412343 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11412343 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11412343 | pubmed:pagination | 561-6 | lld:pubmed |
| pubmed-article:11412343 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:meshHeading | pubmed-meshheading:11412343... | lld:pubmed |
| pubmed-article:11412343 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11412343 | pubmed:articleTitle | The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats. | lld:pubmed |
| pubmed-article:11412343 | pubmed:affiliation | ICSM Endocrine Unit, ICSM, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK. | lld:pubmed |
| pubmed-article:11412343 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11412343 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11412343 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11412343 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11412343 | lld:pubmed |
